

25 Jan 2022 | News

Ponvory's Regulatory Timeline At The US FDA And EMA

by Sue Sutter

Janssen's ponesimod for relapsing multiple sclerosis had a slightly faster review in the US.

[Click here to explore this interactive content online](#) 